Abstract
Center for Biologics Evaluation and Research enhances and supports regulatory decision-making and policy development. This work contributes to our regulatory mission, advances medical product development, and supports Food and Drug Administration’s regulatory response to public health crises. This review presents some examples of our diverse scientific work undertaken in recent years to support our regulatory and public health mission.
Highlights
The Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) has regulatory oversight of blood, tissues, and complex medical products that include vaccines, allergenic products, blood-derived products, certain diagnostics and devices, live biotherapeutics, and novel medical products, such as stem cell-derived products, and other cell and gene therapies.The complex biological products regulated by CBER present a variety of challenges:(1) The challenge of ensuring product sterility, i.e., the absence of unwanted infectious agents, is compounded with the use of biological materials in the manufacture of biological products
The complex biological products regulated by CBER present a variety of challenges: [1] The challenge of ensuring product sterility, i.e., the absence of unwanted infectious agents, is compounded with the use of biological materials in the manufacture of biological products
A recent example of the work being performed by the consortium is the development of a new method to predict differentiated functional capacity of human mesenchymal stem cells after osteogenic induction
Summary
This work contributes to our regulatory mission, advances medical product development, and supports Food and Drug Administration’s regulatory response to public health crises. This review presents some examples of our diverse scientific work undertaken in recent years to support our regulatory and public health mission
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.